Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 196.91% and Operating profit at 48.07% over the last 5 years
2
The company has declared Negative results for the last 5 consecutive quarters
3
With ROE of 0.29%, it has a very expensive valuation with a 8.35 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 13,104 Million (Mid Cap)
173.00
NA
0.00%
-0.27
4.71%
9.05
Revenue and Profits:
Net Sales:
79 Million
(Quarterly Results - Mar 2026)
Net Profit:
18 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.15%
0%
3.15%
6 Months
13.55%
0%
13.55%
1 Year
32.89%
0%
32.89%
2 Years
96.53%
0%
96.53%
3 Years
-29.27%
0%
-29.27%
4 Years
-57.7%
0%
-57.7%
5 Years
0%
0%
0.0%
Shanghai Yizhong Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
196.91%
EBIT Growth (5y)
48.07%
EBIT to Interest (avg)
80.83
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.18
Tax Ratio
39.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
32.26%
ROE (avg)
7.02%
Valuation key factors
Factor
Value
P/E Ratio
173
Industry P/E
Price to Book Value
7.65
EV to EBIT
228.72
EV to EBITDA
201.17
EV to Capital Employed
7.65
EV to Sales
34.51
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3.35%
ROE (Latest)
4.42%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
79.20
72.90
8.64%
Operating Profit (PBDIT) excl Other Income
11.70
11.30
3.54%
Interest
0.10
0.00
Exceptional Items
-0.40
-0.20
-100.00%
Consolidate Net Profit
18.20
13.90
30.94%
Operating Profit Margin (Excl OI)
147.60%
103.10%
4.45%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 8.64% vs -11.96% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 30.94% vs 9.45% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
315.00
172.50
82.61%
Operating Profit (PBDIT) excl Other Income
57.70
-4.10
1,507.32%
Interest
0.10
0.80
-87.50%
Exceptional Items
-2.40
2.80
-185.71%
Consolidate Net Profit
64.60
7.00
822.86%
Operating Profit Margin (Excl OI)
138.60%
-92.80%
23.14%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 82.61% vs -51.95% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 822.86% vs -95.67% in Dec 2024
About Shanghai Yizhong Pharmaceutical Co., Ltd. 
Shanghai Yizhong Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






